Coenzyme Q10 Supplementation Ameliorates Inflammatory Markers In Patients With Multiple Sclerosis: A Double Blind, Placebo, Controlled Randomized Clinical Trial

Effect Decrease
Values Expanded Disability Status Scale. Mean and SD. Placebo: before 1.95 ± 1.1, after 1.95 ± 1.1. Intervention: before 1.88 ± 1.2 , after 1.79 ± 1.2.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 48
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 48 participants with relapsing-remitting multiple sclerosis took 500 mg of coenzyme q10 or placebo daily for 12 weeks.

There was a greater reduction in TNF and IL-6 in the intervention group than the placebo group, the difference being statistically significant. Matrix metallopeptidase was also lowered significantly more, while TGF-β, IL-4, and disability scale results didn't show statistically significant differences.